Maite Gorostegui Obanos
Investigador
Research group
SJD Barcelona Children's Hospital Last Publications
- Cappellano A, Gorostegui M, Gonzalez-Ramella O, Filho NPC, Valencia D, Chantada L, Sampor C, Serrano MJ, Macedo C, Ramirez O, Sardinas S, Lezcano E, Calderón P, Gamboa Y, Fu L, Gómez W, Schelotto M, Ugaz C, Lobos P, Aguiar SDS, Moreno K, Palma J, Sánchez G, Moschella F, Gassant PYH, Velasquez T, Quintero K, Moreno F, Villarroel M, Fuentes Alabi S, Vasquez L, Challinor J and Chantada G International Society of Paediatric Oncology (SIOP) Global Mapping Programme: Latin American Society of Pediatric Oncology (SLAOP) country-level report PEDIATRIC BLOOD & CANCER . 71(6): .
- Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects. Frontiers in oncology . 14: 1380917-1380917.
- Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy Cancers . 16(9): .
Projects
- Project name:
- Multi-ómica y cribado masivo de fármacos para el tratamiento dirigido del Neuroblastoma resistente al tratamiento
- Leader
- Cinzia Emilia Lavarino , Marta García López
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI23/00120
- Starting - finishing date:
- 2024 - 2026
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.